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Hypertension is the leading risk factor of mortality in Nepal accounting for 33000 deaths in 2016. However,
more than 50% of the hypertensive patients are unaware of their status. We participated in the May Measurement
Month 2017 (MMM17) project initiated worldwide by the International Society of Hypertension to raise the aware-
ness on the importance of blood pressure (BP) screening. In this paper, we discuss the screening results of MMM17
in Nepal. An opportunistic cross-sectional survey of volunteers aged 18years was carried out in May 2017 follow-
ing the standard MMM protocol. Data were collected from 18 screening sites in 7 districts covering 5 provinces.
Screenings were conducted either in health facilities, public places, or participants’ homes. Trained volunteers
with health science background and female community health volunteers were mobilized to take part in the
screening. A total of 5972 individuals were screened and of 5968 participants, for whom a mean of the 2nd and
3rd readings was available, 1456 (24.4%) participants had hypertension; 908 (16.8%) of those not receiving treat-
ment were hypertensive; and 248 (45.2%) of those being treated had uncontrolled BP. MMM17 is the first nation-
wide BP screening campaign undertaken in Nepal. Given the suboptimal treatment and control rates identified in
the study, there is a strong imperative to scale up hypertension prevention, screening, and management pro-
grammes. These results suggest that opportunistic screening can identify significant numbers with hypertension.
Mobilization of existing volunteer networks and support of community stakeholders, would be necessary to im-
prove the overall impact and sustainability of future screening programmes.
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Introduction
Raised blood pressure (BP) is a major health problem in the
Nepalese population, with various surveys reporting high
prevalence rates.1–4 However, the control rate of hyperten-
sion is low because of low awareness and treatment rates.
Raising awareness about the adverse consequences of
elevated BP is a key step for preventing complications of
hypertension.5,6 Blood pressure screening is a relatively
low-cost effective health promotion strategy that can be
implemented in a large scale and is sustainable in the long
term.6 It can raise awareness and identify undiagnosed
cases of hypertension particularly in low- and middle-in-
come countries like Nepal where people have limited ac-
cess to healthcare.
May Measurement Month 2017 (MMM17) was initiated as
a global campaign by the International Society of
Hypertension (ISH) to raise awareness of hypertension,
which targeted adults (aged 18 years) who have not had
their BPs measured for at least a year.7 In Nepal, the cam-
paign lasted for 2 months in May and June of 2017. In this
paper, we present the results from this campaign and delib-
erate some lessons for future campaigns.
Methods
This paper used the data from MMM17 conducted in Nepal.7
Sitting BP was measured three times according to standard-
ized specified methods. Both digital (OMRON) and manual
sphygmomanometers were used for BP measurements.
Data were collected using a paper-based questionnaire.
The ethical clearance was obtained from the Nepal Health
Research Council (Approval: 102/2018). A total of 18 sites in
7 districts were covered from 5 provinces (except Province
2 and Province 6). Volunteers with a bachelor’s degree in
health sciences/medicine conducted the BP screening. We
also mobilized trained female community health volunteers
(FCHVs) for screening BP who collected nearly half of the
data for MMM17. Screening was conducted either in health
facilities or at participants’ homes (for FCHVs).
People with systolic BP (SBP) 140mmHg or higher and/or
diastolic BP (DBP) 90mmHg or higher were classified as hy-
pertensive, along with people on anti-hypertensive treat-
ment.8 The description and methods of measurement for
other study variables has been presented elsewhere.7 Data
cleaning was done locally with further cleaning done after
submission to ISH. Data for this study were analysed cen-
trally by the MMM project team.7
Results
Data from 5972 participants were collected during MMM17
(see Supplementary material online, Table S1). More
women thanmen (63% vs. 37%) were screened. Mean age of
the participants was 39.36 16years and mean body mass
index (BMI) was 23.26 4.3 kg/m2. About 548 (40.8%)
reported taking anti-hypertensive medication. Around 75%
of participants had BP measurements taken on the left
arm. Of 5972 screened, 203 (3.4%) reported having type 2
diabetes, 62 (1%) reported a history of myocardial
infarction, and 38 (0.6%) reported a history of stroke. Of
5193 participants with three BP readings, the 3rd reading
was lower compared with the first reading on average by
2.6/1.5mmHg. The mean of 2nd and 3rd readings
(118.6/78.4mmHg) was lower for both SBP and DBP
compared with mean of the 1st and 2nd readings (120/
79.2mmHg) (see Supplementary material online, Table S2).
The age and sex-standardized mean BP for the screened
population was 120.8/79.5 mmHg. For those who were not
taking anti-hypertensive medication standardized mean BP
was 119.8/79.1 mmHg and for those taking anti-hyperten-
sive medication it was 131.3/85 mmHg (see Supplementary
material online, Table 3).
Of the 5968 participants for whom mean of the 2nd and
3rd readings was available or known to be on anti-hyper-
tensive treatment, 1456 (24.4%) participants were hyper-
tensive; 908 were hypertensive and not receiving
treatment, which was 16.8% of the total not receiving
treatment. About 248 (45.2%) of the 548 receiving treat-
ment had uncontrolled BP (see Supplementary material on-
line, Table S4). These proportions were similar before and
after imputation analysis.
After adjustment for age and sex, people receiving anti-
hypertensive medication had significantly higher SBPs and
DBPs. Smoking and alcohol intake were associated with
significant increases in both SBPs and DBPs. In contrast,
DBP readings were significantly lower in pregnant women
and higher in the left arm than readings from the compara-
tor groups (i.e. non-pregnant and readings on the right
arm, respectively; see Supplementary material online,
Table S5 and Figure S1). After adjustment for age, sex,
and anti-hypertensive medication, there was a significant
increase in both mean SBP and DBP across successive BMI
categories (see Supplementary material online, Table S6
and Figure S2).
Discussion
This campaign found that nearly a quarter of participants
were hypertensive; 16.8% of those not receiving treatment
were hypertensive and nearly half those being treated had
uncontrolled BP. Even in well-adjusted models, anti-hyper-
tensive medication (vs. those not receiving treatment),
currently smoking (vs. non-smoker), alcohol intake (one or
more per week vs. never/rarely) were associated with sig-
nificantly higher DBPand SBP.
Although MMM17 was an opportunistic screening, the
findings are compatible with previous prevalence studies
conducted in Nepal. An earlier study of 2815 participants
(1844 were women), aged between 25 and 65 years from
Western Nepal showed that nearly 28% of community resi-
dents were hypertensive.4 A larger nationwide study of
13598 participants who were drawn randomly from all
seven provinces found a slightly lower prevalence of hyper-
tension (18%, 95% CI: 16.7–19.2) among aged 15–69 years.3
Excluding aged 15–29 years, the prevalence stood around
26.7% which is comparable with the current screening esti-
mates.4 The treatment rate in the current study was twice
that observed in the nationwide study (449/2438¼ 18.4%)
while the control rate (233/449¼ 51.8%) was comparable.3
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Screening campaigns like MMM help identify undetected
and inadequately treated cases of hypertension. However,
such programmes alone are not adequate for the long-term
management of hypertension. Therefore, we recommend
strengthening primary and community care services
through the gradual integration of BP screening in existing
delivery platforms, for example, HIV, tuberculosis, or re-
productive health services. Although some figures obtained
from our analysis are comparable with previous national
and regional studies, we do not claim our study findings to
be representative to a larger population due to the nature
of convenience sampling. The critical lessons learnt from
this campaign are primarily that hypertension screening
can be conducted locally making use of existing volunteer
networks, reducing overall financial cost of the pro-
gramme; and secondarily that a BP screening programme
needs the support of community stakeholders, tomaximize
population level coverage, as well as to maintain sustain-
ability. These lessons will be crucial for us in continuing this
campaign in the future.
Supplementary material
Supplementary material is available at European Heart
Journal - Supplements online.
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